Nexalin Technology, Inc. 8-K

What Happened
Nexalin Technology, Inc. (NXL) filed an 8-K reporting that on April 17, 2026 it entered into a Scope of Work (SOW) with U.K.-based clinical research organization Lindus Health to conduct the company’s pivotal clinical trial for the HALO Clarity device. The company also issued a press release on April 22, 2026 announcing advancement of the pivotal study.

Key Details

• The SOW is governed by a previously executed Master Services Agreement and runs until completion of the described services, unless terminated per the MSA.
• Direct fees under the SOW total approximately $944,820, plus certain pass-through expenses; direct fees are payable on a milestone basis and pass-through costs are invoiced monthly.
• The SOW requires formal change orders for certain changes (e.g., new sites, increased enrollment, protocol amendments, extended duration, or additional platform features), which can alter scope, budget, or timeline.
• The April 22 press release announcing study advancement is attached as Exhibit 99.1 to the filing.

Why It Matters
This agreement represents a concrete operational and financial step toward completing Nexalin’s pivotal trial for HALO Clarity. The stated fee commitment (~$944,820) and milestone payment structure give investors a clearer view of near-term cash obligations and project progress. The change-order provisions mean the total cost or timeline could increase if the trial scope expands or requires amendments, so investors should watch for future updates and disclosures on trial progress and related spending.